Overview

Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants

Status:
Not yet recruiting
Trial end date:
2022-08-07
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, single-dose, Phase I clinical study to evaluate the mass balance and biotransformation, safety and tolerability of SIM0417 in healthy Chinese adult male subjects following a single oral administration of SIM0417 in combination with ritonavir.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Simcere Pharmaceutical Co., Ltd.